Literature DB >> 29522183

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Romain Appay1,2, Emeline Tabouret3,2, Nicolas Macagno1,2, Mehdi Touat4,5, Catherine Carpentier2,5, Carole Colin2,5, François Ducray6,7, Ahmed Idbaih4,5, Karima Mokhtari5,8, Emmanuelle Uro-Coste9,10, Caroline Dehais4, Dominique Figarella-Branger1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29522183      PMCID： PMC5892154          DOI： 10.1093/neuonc/noy014

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  6 in total

Review 1.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

2.  Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Authors:  Emeline Tabouret; Anh Tuan Nguyen; Caroline Dehais; Catherine Carpentier; François Ducray; Ahmed Idbaih; Karima Mokhtari; Anne Jouvet; Emmanuelle Uro-Coste; Carole Colin; Olivier Chinot; Hugues Loiseau; Elisabeth Moyal; Claude-Alain Maurage; Marc Polivka; Emmanuèle Lechapt-Zalcman; Christine Desenclos; David Meyronet; Jean-Yves Delattre; Dominique Figarella-Branger
Journal:  Acta Neuropathol       Date:  2016-08-29       Impact factor: 17.088

3.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

4.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

5.  The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.

Authors:  Patrick S Ward; Chao Lu; Justin R Cross; Omar Abdel-Wahab; Ross L Levine; Gary K Schwartz; Craig B Thompson
Journal:  J Biol Chem       Date:  2012-12-21       Impact factor: 5.486

6.  The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.

Authors:  Hao-Yuan Wang; Kai Tang; Ting-Yu Liang; Wei-Zhong Zhang; Ji-Ye Li; Wen Wang; Hui-Min Hu; Ming-Yang Li; Hui-Qing Wang; Xiao-Zheng He; Zhi-Yuan Zhu; Yan-Wei Liu; Shi-Zhong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-05-31
  6 in total
  5 in total

1.  Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.

Authors:  Cinthya J Zepeda-Mendoza; Rachael A Vaubel; Shabnam Zarei; Cristiane M Ida; Martin Matthews; Sara Acree; Aditya Raghunathan; Caterina Giannini; Robert B Jenkins
Journal:  Acta Neuropathol       Date:  2020-03-13       Impact factor: 17.088

Review 2.  IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.

Authors:  Lidia Gatto; Enrico Franceschi; Alicia Tosoni; Vincenzo Di Nunno; Ilaria Maggio; Raffaele Lodi; Alba Ariela Brandes
Journal:  Mol Diagn Ther       Date:  2021-06-07       Impact factor: 4.476

3.  Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.

Authors:  L Poetsch; C Bronnimann; H Loiseau; J S Frénel; A Siegfried; R Seizeur; G Gauchotte; D Cappellen; C Carpentier; D Figarella-Branger; S Eimer; D Meyronet; F Ducray
Journal:  J Neurooncol       Date:  2020-11-17       Impact factor: 4.506

4.  Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.

Authors:  Lei-Ming Wang; Zhuo Li; Yue-Shan Piao; Yan-Ning Cai; Li-Yan Zhang; Hai-Jing Ge; Wei-Wei Xu; De-Hong Lu
Journal:  Chin Med J (Engl)       Date:  2019-12-20       Impact factor: 6.133

5.  H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Authors:  Aldo Scarpa; Valeria Barresi; Serena Ammendola; Nicolò Caldonazzi; Michele Simbolo; Maria Liliana Piredda; Matteo Brunelli; Pietro Luigi Poliani; Giampietro Pinna; Francesco Sala; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2021-06-24       Impact factor: 4.535
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.